Search
Menu
Home
HTB
2005
April
HTB
April 2005
Contents
Editorial
Volume 6 Number 4 April 2005
Treatment alerts
Drug-induced hepatitis in healthy volunteers receiving rifampicin 600mg daily in combination with ritonavir 100mg and saquinavir 1000mg twice daily (boosted saquinavir)
New European recommendations regarding the co-administration of ddI (Videx) and tenofovir DF (Viread)
Conference reports
12th Conference on Retrovirus and Opportunistic Infections, 22-25 February, Boston, 2005
Developments in nevirapine use in MTCT reduction
Mashi study – late breakers on breastfeeding
Maternal health and infant mortality
Paediatric care in lower income settings
Tenofovir not linked to bone toxicity in children followed for one year
Gut memory CD4 T cells implicated in a central role for HIV disease pathology: dramatic impact prior to seroconversion
Case of multi-drug resistant (MDR) rapid progressor
Case report of antibody reversion and negative viral load four-years after treatment discontinuation
24-week efficacy of TMC114 in PI-experienced patients
Maturation inhibitor shows anti-HIV activity in single dose pilot study
New antiretrovirals at 12th CROI
Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age
Omega-3 supplement effective to reduce triglycerides
Entecavir is effective against 3TC-resistant hepatitis B
Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy
Tenofovir is non-inferior to adefovir for the treatment of hepatitis B in HBV-HIV co-infected patients
Antiretrovirals
500mg saquinavir (Invirase) approved in Europe
Roche discontinue ddC and Fortovase
Needle-free injections for T-20 in US
Treatment access
Demand for two originator ARVs could soon exceed supply
Indian patent bill is introduced with no change: the beginning of the end of generics?
Patent mailbox opened in India
GSK calls on UK to use G8 presidency to enforce patents
India admitted into Bush aid programme in same week that Indian parliament dismantles hope of future generic ARVs
Hepatitis coinfection
Pegasys approved for HIV/hepatitis C coinfection in Europe and US
Pegasys approved in Europea for the treatment of chronic hepatitis B
On the web
Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries
HIV inSite – new online resources
PRN Notebook – December 2004
Bulletin of Experimental Treatments for AIDS
PDFs
Volume 6 Number 4 April 2005 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
Major update of UK PrEP guidelines online for public consultation
1 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage